Search

Your search keyword '"Lenting, Peter J."' showing total 48 results

Search Constraints

Start Over You searched for: Author "Lenting, Peter J." Remove constraint Author: "Lenting, Peter J." Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
48 results on '"Lenting, Peter J."'

Search Results

1. Type 2N von Willebrand disease: genotype drives different bleeding phenotypes and treatment needs

7. Transplacental delivery of therapeutic proteins by engineered immunoglobulin G: a step toward perinatal replacement therapy

11. A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD

15. PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space.

17. Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis

18. Mortality, cardiac and cerebral damages reduction by IL-1 inhibition in a murine model of TTP

19. The Role of Platelets and von Willebrand Factor in the Procoagulant Phenotype of Inflammatory Bowel Disease.

20. Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc

21. The role of platelets and von Willebrand factor in the procoagulant phenotype of inflammatory bowel disease

22. Shear Forces Induced Platelet Clearance Is a New Mechanism of Thrombocytopenia

23. IdeS, a new option to optimize the management of patients with hemophilia A on emicizumab

25. A nanobody against the von Willebrand factor A3-domain detects ADAMTS13-induced proteolysis in congenital & acquired VWD

27. Cerebral Microbleeds During Transcatheter Aortic Valve Replacement: A Prospective Magnetic Resonance Imaging Cohort

29. Microlyse; a thrombolytic agent that targets VWF for clearance of microvascular thrombosis

31. Identification of von Willebrand factor D4 domain mutations in patients of Afro‐Caribbean descent: In vitro characterization

35. VWF/LRP4/αVβ3-axis represents a novel pathway regulating proliferation of human vascular smooth muscle cells.

36. A compact integrated microfluidic oxygenator with high gas exchange efficiency and compatibility for long-lasting endothelialization.

37. Unique humanized mouse models of von Willebrand disease type 2A.

38. Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab

39. Von Willebrand factor: how unique structural adaptations support and coordinate its complex function

41. A nanobody against the von Willebrand factor A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired von Willebrand disease

42. Gene Therapy for Hemophilia.

43. Future needs for continuing innovation in hemophilia: improving outcomes for individuals of all severities, including women and those in resource-constrained regions.

44. von Willebrand disease.

45. Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc.

46. Nonsevere Hemophilia: The Need for a Renewed Focus and Improved Outcomes.

48. The VWF/LRP4/αVβ3-axis represents a novel pathway regulating proliferation of human vascular smooth muscle cells.

Catalog

Books, media, physical & digital resources